

Preface to First Edition	xiii	2.1.2. Sources of Lead Compounds	20
Preface to Second Edition	xv	2.1.2.1. Endogenous Ligands	20
Preface to Third Edition	xvii	2.1.2.2. Other Known Ligands	23
		2.1.2.3. Screening of Compounds	24
<b>1. Introduction</b>	<b>1</b>	2.1.2.3.1. Sources of Compounds for Screening	26
1.1. Overview	1	2.1.2.3.1.1. Natural Products	26
1.2. Drugs Discovered without Rational Design	2	2.1.2.3.1.2. Medicinal Chemistry Collections and Other "Handcrafted" Compounds	27
1.2.1. Medicinal Chemistry Folklore	2	2.1.2.3.1.3. High-Throughput Organic Synthesis	27
1.2.2. Discovery of Penicillins	3	2.1.2.3.1.3.1. Solid-Phase Library Synthesis	27
1.2.3. Discovery of Librium	4	2.1.2.3.1.3.2. Solution-Phase Library Synthesis	30
1.2.4. Discovery of Drugs through Metabolism Studies	5	2.1.2.3.1.3.3. Evolution of HTOS	31
1.2.5. Discovery of Drugs through Clinical Observations	6	2.1.2.3.2. Drug-Like, Lead-Like, and Other Desirable Properties of Compounds for Screening	32
1.3. Overview of Modern Rational Drug Design	7	2.1.2.3.3. Random Screening	36
1.3.1. Overview of Drug Targets	7	2.1.2.3.4. Targeted (or Focused) Screening, Virtual Screening, and Computational Methods in Lead Discovery	36
1.3.2. Identification and Validation of Targets for Drug Discovery	9	2.1.2.3.4.1. Virtual Screening Database	37
1.3.3. Alternatives to Target-Based Drug Discovery	10	2.1.2.3.4.2. Virtual Screening Hypothesis	37
1.3.4. Lead Discovery	11	2.1.2.3.5. Hit-To-Lead Process	43
1.3.5. Lead Modification (Lead Optimization)	12	2.1.2.3.6. Fragment-based Lead Discovery	45
1.3.5.1. Potency	12	2.2. Lead Modification	54
1.3.5.2. Selectivity	12	2.2.1. Identification of the Active Part: The Pharmacophore	55
1.3.5.3. Absorption, Distribution, Metabolism, and Excretion (ADME)	13	2.2.2. Functional Group Modification	57
1.3.5.4. Intellectual Property Position	13	2.2.3. Structure–Activity Relationships	57
1.3.6. Drug Development	13	2.2.4. Structure Modifications to Increase Potency, Therapeutic Index, and ADME Properties	59
1.3.6.1. Preclinical Development	13	2.2.4.1. Homologation	60
1.3.6.2. Clinical Development (Human Clinical Trials)	14	2.2.4.2. Chain Branching	61
1.3.6.3. Regulatory Approval to Market the Drug	14		
1.4. Epilogue	14		
1.5. General References	15		
1.6. Problems	16		
References	16		
<b>2. Lead Discovery and Lead Modification</b>	<b>19</b>		
2.1. Lead Discovery	20		
2.1.1. General Considerations	20		

2.2.4.3. Bioisosterism	62	2.3. General References	95
2.2.4.4. Conformational Constraints and Ring-Chain Transformations	66	2.4. Problems	102
2.2.4.5. Peptidomimetics	68	References	106
2.2.5. Structure Modifications to Increase Oral Bioavailability and Membrane Permeability	72	<b>3. Receptors</b>	<b>123</b>
2.2.5.1. Electronic Effects: The Hammett Equation	72	3.1. Introduction	123
2.2.5.2. Lipophilicity Effects	74	3.2. Drug–Receptor Interactions	125
2.2.5.2.1. Importance of Lipophilicity	74	3.2.1. General Considerations	125
2.2.5.2.2. Measurement of Lipophilicities	74	3.2.2. Important Interactions (Forces) Involved in the Drug–Receptor Complex	125
2.2.5.2.3. Computer Automation of log <i>P</i> Determination	78	3.2.2.1. Covalent Bonds	126
2.2.5.2.4. Membrane Lipophilicity	79	3.2.2.2. Ionic (or Electrostatic) Interactions	126
2.2.5.3. Balancing Potency of Ionizable Compounds with Lipophilicity and Oral Bioavailability	79	3.2.2.3. Ion–Dipole and Dipole–Dipole Interactions	126
2.2.5.4. Properties that Influence Ability to Cross the Blood–Brain Barrier	81	3.2.2.4. Hydrogen Bonds	126
2.2.5.5. Correlation of Lipophilicity with Promiscuity and Toxicity	82	3.2.2.5. Charge–Transfer Complexes	128
2.2.6. Computational Methods in Lead Modification	83	3.2.2.6. Hydrophobic Interactions	129
2.2.6.1. Overview	83	3.2.2.7. Cation– $\pi$ Interaction	130
2.2.6.2. Quantitative Structure–Activity Relationships (QSARs)	83	3.2.2.8. Halogen Bonding	130
2.2.6.2.1. Historical Overview. Steric Effects: The Taft Equation and Other Equations	83	3.2.2.9. van der Waals or London Dispersion Forces	130
2.2.6.2.2. Methods Used to Correlate Physicochemical Parameters with Biological Activity	84	3.2.2.10. Conclusion	131
2.2.6.2.2.1. Hansch Analysis: A Linear Multiple Regression Analysis	84	3.2.3. Determination of Drug–Receptor Interactions	131
2.2.6.2.2.2. Manual Stepwise Methods: Topliss Operational Schemes and Others	85	3.2.4. Theories for Drug–Receptor Interactions	134
2.2.6.2.2.3. Batch Selection Methods: Batchwise Topliss Operational Scheme, Cluster Analysis, and Others	87	3.2.4.1. Occupancy Theory	134
2.2.6.2.2.4. Free and Wilson or de Novo Method	88	3.2.4.2. Rate Theory	137
2.2.6.2.2.5. Computational Methods for ADME Descriptors	89	3.2.4.3. Induced-Fit Theory	137
2.2.6.3. Scaffold Hopping	89	3.2.4.4. Macromolecular Perturbation Theory	137
2.2.6.4. Molecular Graphics-Based Lead Modification	90	3.2.4.5. Activation–Aggregation Theory	138
2.2.7. Epilogue	93	3.2.4.6. The Two-State (Multistate) Model of Receptor Activation	138
		3.2.5. Topographical and Stereochemical Considerations	139
		3.2.5.1. Spatial Arrangement of Atoms	139
		3.2.5.2. Drug and Receptor Chirality	140
		3.2.5.3. Diastereomers	145
		3.2.5.4. Conformational Isomers	146
		3.2.5.5. Atropisomers	149
		3.2.5.6. Ring Topology	151
		3.2.6. Case History of the Pharmacodynamically Driven Design of a Receptor Antagonist: Cimetidine	151
		3.2.7. Case History of the Pharmacokinetically Driven Design of Suvorexant	156
		3.3. General References	157
		3.4. Problems	157
		References	159

<b>4. Enzymes</b>	<b>165</b>		
4.1. Enzymes as Catalysts	165		
4.1.1. What are Enzymes?	165		
4.1.2. How do Enzymes Work?	166		
4.1.2.1. Specificity of Enzyme-Catalyzed Reactions	167		
4.1.2.1.1. Binding Specificity	167		
4.1.2.1.2. Reaction Specificity	168		
4.1.2.2. Rate Acceleration	168		
4.2. Mechanisms of Enzyme Catalysis	169		
4.2.1. Approximation	169		
4.2.2. Covalent Catalysis	170		
4.2.3. General Acid–Base Catalysis	170		
4.2.4. Electrostatic Catalysis	172		
4.2.5. Desolvation	173		
4.2.6. Strain or Distortion	173		
4.2.7. Example of the Mechanisms of Enzyme Catalysis	174		
4.3. Coenzyme Catalysis	175		
4.3.1. Pyridoxal 5'-Phosphate	178		
4.3.1.1. Racemases	178		
4.3.1.2. Decarboxylases	180		
4.3.1.3. Aminotransferases (Formerly Transaminases)	180		
4.3.1.4. PLP-Dependent $\beta$ -Elimination	184		
4.3.2. Tetrahydrofolate and Pyridine Nucleotides	184		
4.3.3. Flavin	189		
4.3.3.1. Two-Electron (Carbanion) Mechanism	190		
4.3.3.2. Carbanion Followed by Two One-Electron Transfers	190		
4.3.3.3. One-Electron Mechanism	192		
4.3.3.4. Hydride Mechanism	192		
4.3.4. Heme	192		
4.3.5. Adenosine Triphosphate and Coenzyme A	195		
4.4. Enzyme Catalysis in Drug Discovery	196		
4.4.1. Enzymatic Synthesis of Chiral Drug Intermediates	196		
4.4.2. Enzyme Therapy	198		
4.5. General References	198		
4.6. Problems	199		
References	202		
<b>5. Enzyme Inhibition and Inactivation</b>	<b>207</b>		
5.1. Why Inhibit an Enzyme?	208		
5.2. Reversible Enzyme Inhibitors	210		
5.2.1. Mechanism of Reversible Inhibition	210		
5.2.2. Selected Examples of Competitive Reversible Inhibitor Drugs	211		
5.2.2.1. Simple Competitive Inhibition	211		
5.2.2.1.1. Epidermal Growth Factor Receptor Tyrosine Kinase as a Target for Cancer	211		
5.2.2.1.2. Discovery and Optimization of EGFR Inhibitors	212		
5.2.2.2. Stabilization of an Inactive Conformation: Imatinib, an Antileukemia Drug	213		
5.2.2.2.1. The Target: Bcr-Abl, a Constitutively Active Kinase	213		
5.2.2.2.2. Lead Discovery and Modification	214		
5.2.2.2.3. Binding Mode of Imatinib to Abl Kinase	215		
5.2.2.2.4. Inhibition of Other Kinases by Imatinib	216		
5.2.2.3. Alternative Substrate Inhibition: Sulfonamide Antibacterial Agents (Sulfa Drugs)	217		
5.2.2.3.1. Lead Discovery	217		
5.2.2.3.2. Lead Modification	217		
5.2.2.3.3. Mechanism of Action	217		
5.2.3. Transition State Analogs and Multisubstrate Analogs	219		
5.2.3.1. Theoretical Basis	219		
5.2.3.2. Transition State Analogs	220		
5.2.3.2.1. Enalaprilat	220		
5.2.3.2.2. Pentostatin	221		
5.2.3.2.3. Forodesine and DADMe-ImmH	222		
5.2.3.2.4. Multisubstrate Analogs	223		
5.2.4. Slow, Tight-Binding Inhibitors	225		
5.2.4.1. Theoretical Basis	225		
5.2.4.2. Captopril, Enalapril, Lisinopril, and Other Antihypertensive Drugs	225		
5.2.4.2.1. Humoral Mechanism for Hypertension	225		
5.2.4.2.2. Lead Discovery	226		
5.2.4.2.3. Lead Modification and Mechanism of Action	226		
5.2.4.2.4. Dual-Acting Drugs: Dual-Acting Enzyme Inhibitors	230		
5.2.4.3. Lovastatin (Mevinolin) and Simvastatin, Antihypercholesterolemic Drugs	232		
5.2.4.3.1. Cholesterol and Its Effects	232		
5.2.4.3.2. Lead Discovery	232		
5.2.4.3.3. Mechanism of Action	233		
5.2.4.3.4. Lead Modification	234		
5.2.4.4. Saxagliptin, a Dipeptidyl Peptidase-4 Inhibitor and Antidiabetes Drug	234		

5.2.5. Case History of Rational Drug Design of an Enzyme Inhibitor: Ritonavir	235	6.3. Classes of Drugs that Interact with DNA	287
5.2.5.1. Lead Discovery	235	6.3.1. Reversible DNA Binders	288
5.2.5.2. Lead Modification	236	6.3.1.1. External Electrostatic Binding	289
5.3. Irreversible Enzyme Inhibitors	238	6.3.1.2. Groove Binding	289
5.3.1. Potential of Irreversible Inhibition	238	6.3.1.3. Intercalation and Topoisomerase-Induced DNA Damage	290
5.3.2. Affinity Labeling Agents	240	6.3.1.3.1. Amsacrine, an Acridine Analog	292
5.3.2.1. Mechanism of Action	240	6.3.1.3.2. Dactinomycin, the Parent Actinomycin Analog	293
5.3.2.2. Selected Affinity Labeling Agents	241	6.3.1.3.3. Doxorubicin (Adriamycin) and Daunorubicin (Daunomycin), Anthracycline Antitumor Antibiotics	294
5.3.2.2.1. Penicillins and Cephalosporins/ Cephameycins	241	6.3.1.3.4. <i>Bis</i> -intercalating Agents	295
5.3.2.2.2. Aspirin	243	6.3.2. DNA Alkylators	295
5.3.3. Mechanism-Based Enzyme Inactivators	247	6.3.2.1. Nitrogen Mustards	295
5.3.3.1. Theoretical Aspects	247	6.3.2.1.1. Lead Discovery	295
5.3.3.2. Potential Advantages in Drug Design Relative to Affinity Labeling Agents	247	6.3.2.1.2. Chemistry of Alkylating Agents	296
5.3.3.3. Selected Examples of Mechanism-Based Enzyme Inactivators	248	6.3.2.1.3. Lead Modification	297
5.3.3.3.1. Vigabatrin, an Anticonvulsant Drug	248	6.3.2.2. Ethylenimines	299
5.3.3.3.2. Eflornithine, an Antiprotozoal Drug and Beyond	250	6.3.2.3. Methanesulfonates	299
5.3.3.3.3. Tranylcypromine, an Antidepressant Drug	253	6.3.2.4. (+)-CC-1065 and Duocarmycins	300
5.3.3.3.4. Selegiline (l-Deprenyl) and Rasagiline: Antiparkinsonian Drugs	254	6.3.2.5. Metabolically Activated Alkylating Agents	301
5.3.3.3.5. 5-Fluoro-2'-deoxyuridylate, Floxuridine, and 5-Fluorouracil: Antitumor Drugs	256	6.3.2.5.1. Nitrosoureas	301
5.4. General References	258	6.3.2.5.2. Triazene Antitumor Drugs	303
5.5. Problems	261	6.3.2.5.3. Mitomycin C	303
References	265	6.3.2.5.4. Leinamycin	305
<b>6. DNA-Interactive Agents</b>	<b>275</b>	6.3.3. DNA Strand Breakers	307
6.1. Introduction	275	6.3.3.1. Anthracycline Antitumor Antibiotics	307
6.1.1. Basis for DNA-Interactive Drugs	275	6.3.3.2. Bleomycin	308
6.1.2. Toxicity of DNA-Interactive Drugs	276	6.3.3.3. Tirapazamine	310
6.1.3. Combination Chemotherapy	276	6.3.3.4. Eneidyne Antitumor Antibiotics	311
6.1.4. Drug Interactions	277	6.3.3.4.1. Esperamicins and Calicheamicins	313
6.1.5. Drug Resistance	277	6.3.3.4.2. Dynemicin A	314
6.2. DNA Structure and Properties	277	6.3.3.4.3. Neocarzinostatin (Zinostatin)	314
6.2.1. Basis for the Structure of DNA	277	6.3.3.5. Sequence Specificity for DNA-Strand Scission	317
6.2.2. Base Tautomerization	279	6.4. General References	319
6.2.3. DNA Shapes	280	6.5. Problems	319
6.2.4. DNA Conformations	286	References	320
<b>7. Drug Resistance and Drug Synergism</b>	<b>333</b>		
7.1. Drug Resistance	333		
7.1.1. What is Drug Resistance?	333		
7.1.2. Mechanisms of Drug Resistance	334		
7.1.2.1. Altered Target Enzyme or Receptor	334		

7.1.2.2. Overproduction of the Target Enzyme or Receptor	340	8.4.2.1.8. Other Oxidative Reactions	387
7.1.2.3. Overproduction of the Substrate or Ligand for the Target Protein	341	8.4.2.1.9. Alcohol and Aldehyde Oxidations	387
7.1.2.4. Increased Drug-Destroying Mechanisms	341	8.4.2.2. Reductive Reactions	388
7.1.2.5. Decreased Prodrug-Activating Mechanism	344	8.4.2.2.1. Carbonyl Reduction	388
7.1.2.6. Activation of New Pathways Circumventing the Drug Effect	344	8.4.2.2.2. Nitro Reduction	389
7.1.2.7. Reversal of Drug Action	344	8.4.2.2.3. Azo Reduction	390
7.1.2.8. Altered Drug Distribution to the Site of Action	346	8.4.2.2.4. Azido Reduction	390
7.2. Drug Synergism (Drug Combination)	346	8.4.2.2.5. Tertiary Amine Oxide Reduction	390
7.2.1. What is Drug Synergism?	346	8.4.2.2.6. Reductive Dehalogenation	391
7.2.2. Mechanisms of Drug Synergism	346	8.4.2.3. Carboxylation Reaction	391
7.2.2.1. Inhibition of a Drug-Destroying Enzyme	346	8.4.2.4. Hydrolytic Reactions	391
7.2.2.2. Sequential Blocking	348	8.4.3. Phase II Transformations: Conjugation Reactions	393
7.2.2.3. Inhibition of Targets in Different Pathways	349	8.4.3.1. Introduction	393
7.2.2.4. Efflux Pump Inhibitors	350	8.4.3.2. Glucuronic Acid Conjugation	395
7.2.2.5. Use of Multiple Drugs for the Same Target	350	8.4.3.3. Sulfate Conjugation	397
7.3. General References	352	8.4.3.4. Amino Acid Conjugation	398
7.4. Problems	352	8.4.3.5. Glutathione Conjugation	399
References	352	8.4.3.6. Water Conjugation	400
		8.4.3.7. Acetyl Conjugation	400
		8.4.3.8. Fatty Acid and Cholesterol Conjugation	403
		8.4.3.9. Methyl Conjugation	403
		8.4.4. Toxicophores and Reactive Metabolites (RMs)	405
		8.4.5. Hard and Soft (Antedugs) Drugs	405
		8.5. General References	407
		8.6. Problems	408
		References	411
<b>8. Drug Metabolism</b>	<b>357</b>	<b>9. Prodrugs and Drug Delivery Systems</b>	<b>423</b>
8.1. Introduction	357	9.1. Enzyme Activation of Drugs	423
8.2. Synthesis of Radioactive Compounds	359	9.1.1. Utility of Prodrugs	424
8.3. Analytical Methods in Drug Metabolism	361	9.1.1.1. Aqueous Solubility	424
8.3.1. Sample Preparation	361	9.1.1.2. Absorption and Distribution	424
8.3.2. Separation	361	9.1.1.3. Site Specificity	424
8.3.3. Identification	362	9.1.1.4. Instability	424
8.3.4. Quantification	363	9.1.1.5. Prolonged Release	424
8.4. Pathways for Drug Deactivation and Elimination	363	9.1.1.6. Toxicity	424
8.4.1. Introduction	363	9.1.1.7. Poor Patient Acceptability	424
8.4.2. Phase I Transformations	365	9.1.1.8. Formulation Problems	424
8.4.2.1. Oxidative Reactions	365	9.1.2. Types of Prodrugs	424
8.4.2.1.1. Aromatic Hydroxylation	368	9.2. Mechanisms of Drug Inactivation	425
8.4.2.1.2. Alkene Epoxidation	373	9.2.1. Carrier-Linked Prodrugs	425
8.4.2.1.3. Oxidations of Carbons Adjacent to sp <sup>2</sup> Centers	373	9.2.1.1. Carrier Linkages for Various Functional Groups	425
8.4.2.1.4. Oxidation at Aliphatic and Alicyclic Carbon Atoms	374	9.2.1.1.1. Alcohols, Carboxylic Acids, and Related	425
8.4.2.1.5. Oxidations of Carbon–Nitrogen Systems	375	9.2.1.1.2. Amines and Amidines	427
8.4.2.1.6. Oxidations of Carbon–Oxygen Systems	385	9.2.1.1.3. Sulfonamides	428
8.4.2.1.7. Oxidations of Carbon–Sulfur Systems	385	9.2.1.1.4. Carbonyl Compounds	428

9.2.1.2. Examples of Carrier-Linked Bipartite Prodrugs	428	9.2.2.3. Hydrolytic Activation	445
9.2.1.2.1. Prodrugs for Increased Water Solubility	428	9.2.2.4. Elimination Activation	445
9.2.1.2.2. Prodrugs for Improved Absorption and Distribution	429	9.2.2.5. Oxidative Activation	446
9.2.1.2.3. Prodrugs for Site Specificity	429	9.2.2.5.1. N- and O-Dealkylations	446
9.2.1.2.4. Prodrugs for Stability	433	9.2.2.5.2. Oxidative Deamination	447
9.2.1.2.5. Prodrugs for Slow and Prolonged Release	434	9.2.2.5.3. N-Oxidation	448
9.2.1.2.6. Prodrugs to Minimize Toxicity	434	9.2.2.5.4. S-Oxidation	450
9.2.1.2.7. Prodrugs to Encourage Patient Acceptance	435	9.2.2.5.5. Aromatic Hydroxylation	451
9.2.1.2.8. Prodrugs to Eliminate Formulation Problems	435	9.2.2.5.6. Other Oxidations	451
9.2.1.3. Macromolecular Drug Carrier Systems	435	9.2.2.6. Reductive Activation	452
9.2.1.3.1. General Strategy	435	9.2.2.6.1. Azo Reduction	452
9.2.1.3.2. Synthetic Polymers	436	9.2.2.6.2. Azido Reduction	453
9.2.1.3.3. Poly( $\alpha$ -Amino Acids)	436	9.2.2.6.3. Sulfoxide Reduction	453
9.2.1.3.4. Other Macromolecular Supports	438	9.2.2.6.4. Disulfide Reduction	453
9.2.1.4. Tripartite Prodrugs	438	9.2.2.6.5. Nitro Reduction	454
9.2.1.5. Mutual Prodrugs (also called Codrugs)	443	9.2.2.7. Nucleotide Activation	454
9.2.2. Bioprecursor Prodrugs	443	9.2.2.8. Phosphorylation Activation	455
9.2.2.1. Origins	443	9.2.2.9. Sulfation Activation	457
9.2.2.2. Proton Activation: An Abbreviated Case History of the Discovery of Omeprazole	444	9.2.2.10. Decarboxylation Activation	457
		9.3. General References	459
		9.4. Problems	459
		References	461
		Appendix	469
		Index	507

Please look for the Student/companion site at <http://booksite.elsevier.com/9780123820303>

Please look for the Instructor site (coming soon) at <http://textbooks.elsevier.com/web/manuals.aspx?isbn=9780123820303>